Trial reportThe Journal of infectious diseases2012
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
Trial report in The Journal of infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00090779 (The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis.PloS one · 2013Pooled it
- Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217.Journal of acquired immune deficiency syndromes (1999) · 2017Trial
- A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection.PloS one · 2015Trial
- Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.Lancet (London, England) · 2013Trial
- Short-course antiretroviral therapy in primary HIV infection.The New England journal of medicine · 2013Trial
- Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.PloS one · 2013Trial
- No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.PLoS medicine · 2012Trial
- Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control.Current opinion in HIV and AIDS · 2026Review
- Rapid viral suppression using integrase inhibitors during acute HIV-1 infection.The Journal of antimicrobial chemotherapy · 2025Article
- Review
- Imaging and biopsy of HIV-infected individuals undergoing analytic treatment interruption.Frontiers in medicine · 2022Article
- Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.AIDS (London, England) · 2020Article
- The effect of "universal test and treat" program on HIV treatment outcomes and patient survival among a cohort of adults taking antiretroviral treatment (ART) in low income settings of Gurage zone, South Ethiopia.AIDS research and therapy · 2020Article
- Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study.Pathogens & immunity · 2020Article
- Integrase strand-transfer inhibitors for treatment of early HIV infection: A case series.Medicine · 2019Article
- Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality.AIDS research and human retroviruses · 2018Article
- The costs of HIV treatment and care in Ghana.AIDS (London, England) · 2017Article
- Primary HIV Infection: Clinical Presentation, Testing, and Treatment.Current infectious disease reports · 2017Review
- Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.The Journal of infectious diseases · 2017Review
- Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.Journal of acquired immune deficiency syndromes (1999) · 2017Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
backgroundThe benefits of antiretroviral therapy during early human immunodeficiency virus type 1 (HIV-1) infection remain unproved.
methodsA5217 study team randomized patients within 6 months of HIV-1 seroconversion to receive either 36 weeks of antiretrovirals (immediate treatment [IT]) or no treatment (deferred treatment [DT]). Patients were to start or restart antiretroviral therapy if they met predefined criteria. The primary end point was a composite of requiring treatment or retreatment and the log(10) HIV-1 RNA level at week 72 (both groups) and 36 (DT group).
resultsAt the June 2009 Data Safety Monitoring Board (DSMB) review, 130 of 150 targeted participants had enrolled. Efficacy analysis included 79 individuals randomized ≥72 weeks previously. For the primary end point, the IT group at week 72 had a better outcome than the DT group at week 72 (P = .005) and the DT group at week 36 (P = .002). The differences were primarily due to the higher rate of progression to needing treatment in the DT group (50%) versus the IT (10%) group. The DSMB recommended stopping the study because further follow-up was unlikely to change these findings.
conclusionsProgression to meeting criteria for antiretroviral initiation in the DT group occurred more frequently than anticipated, limiting the ability to evaluate virologic set point. Antiretrovirals during early HIV-1 infection modestly delayed the need for subsequent treatment. CLINICAL TRIALS REGISTRATION: NCT00090779.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.